Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAT8008 in Advanced Solid Tumors
NCT05620017Phase 1Recruiting
- Sponsor
- Bio-Thera Solutions, Ltd.
- Start
- Nov 2022
- Primary completion
- May 2027
- Countries
- 1
01
Overview
Phase 1, open-label trial of BAT8008 in solid tumor (advanced stage) (5 arms), sponsored by Bio-Thera Solutions, Ltd. Primary endpoints: Dose limiting toxicity at 21 days and Maximum tolerated dose at 21 days. Started Nov 2022; status: recruiting.
02
Drugs
BAT8008
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05620017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05620017.